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Abstract
Erythropoietin (EPO) is a 30.4 kDa glycoprotein produced by the kidney, and is mostly well-known for its
physiological function in regulating red blood cell production in the bone marrow. Accumulating evidence,
however, suggests that EPO has additional organ protective effects, which may be useful in the prevention or
treatment of acute kidney injury. These protective mechanisms are multifactorial in nature and include inhibition of
apoptotic cell death, stimulation of cellular regeneration, inhibition of deleterious pathways, and promotion of
recovery.
In this article, we review the physiology of EPO, assess previous work that supports the role of EPO as a general
tissue protective agent, and explain the mechanisms by which it may achieve this tissue protective effect. We then
focus on experimental and clinical data that suggest that EPO has a kidney protective effect.
Introduction
Erythropoietin (EPO) is a complex molecule, which
regulates red blood cell production in the bone mar-
row. Recombinant human EPO (rHuEPO) is commer-
cially available and is widely used for the treatment of
anemia. In recent years, additional nonerythropoietic
tissue/organ protective properties of EPO have
become apparent, in particular for kidneys. In this
article, we consider the evidence supporting EPO as a
general tissue protective drug and discuss the poten-
tial mechanisms by which it may achieve this general
effect. We then focus on the renal protective effects of
EPO and the potential mechanisms through which it
may confer this specific protection. Finally, we review
the experimental studies and clinical trials of EPO in
a c u t ek i d n e yi n j u r y( A K I ) –discuss risks, lessons
learned, and the need for further randomized studies
in humans before any change in clinical practice is
considered.
The physiological properties of EPO
The structure of the EPO molecule
EPO is a 30.4 kD glycoprotein and class I cytokine con-
sisting of 165 amino acids [1]. EPO has four acidic oli-
gosaccharide side chains (3 N-linked and 1 O-linked)
and contains up to 14 sialic acid residues. Its carbohy-
drate portion contributes 40% of its molecular weight
[1]. The N-linked polysaccharide side chains appear to
be important for the biosynthesis and secretion of EPO,
enhance its stability in blood, and limit hepatic clear-
ance, thus facilitating the systemic transit of EPO from
kidney to bone marrow [2].
The variable nature of the sialic acid content gives rise
to EPO isoforms with differences in charge. As the num-
ber of sialic acid groups on the carbohydrate portion of
EPO increase, so does its serum half-life (Table 1),
whereas receptor-binding capacity decreases [3-7]. Clear-
ance, however, appears to have a stronger influence on in
vivo activity than receptor-binding affinity.
Each EPO molecule has two EPO receptor (EPOR)
binding sites. There are two affinities of the EPOR for
EPO in solution: one of high and one of low affinity
(needs 1,000 times the concentration of EPO for activa-
tion) [8].
Physiological stimuli for EPO production/release
Approximately 90% of systemic EPO in adults is pro-
duced by peritubular interstitial fibroblasts in the renal
cortex and outer medulla of the kidney. A feedback
mechanism involving oxygen delivery to the tissues
appears to regulate EPO production [9]. Hypoxia-induci-
ble factor (HIF) regulates transcription of the EPO gene
in the kidney, which determines EPO synthesis. This
process is dependent on local oxygen tension. HIF is
quickly destroyed in well-oxygenated cells through
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some) by the von Hippel-Landau tumor suppressor pro-
tein (pVHL), but when oxygen delivery decreases, pVHL
ceases its proteolysis of HIF, increasing the levels of
HIF, which subsequently increases EPO production
[10,11].
Structure of EPO receptors
The EPO receptor (EPOR) is a 66 kD membrane glyco-
protein typically consisting of 484 amino acids and 2
peptide chains; it belongs to a large cytokine and growth
factor receptor family [3]. Binding studies have demon-
strated that the EPOR has different affinities for EPO
Table 1 Animal studies of EPO in AKI: ischemia-reperfusion models
Year Type AKI model/follow-up EPO dose Outcome
2009 Dogs IR: nephrectomy, 2 weeks recovery, then
renal artery occlusion, ischemia 1 hr;
reperfusion 28 days
EPO 500 U/kg i.v. before ischemia ±
90 min abdominal insufflation
↓microalbuminuria, ↑renal function recovery at 4
weeks; i.v. EPO better than mannitol for renal I-R
injury protection
2009 Rats IR: transplanted with male bone marrow
cells; reperfusion 2 or 4 weeks
EPO 5000 U 30 minutes before
ischemia
↑GFR (4 weeks), ®proteinuria/Hb (2 and 4 weeks),
↓tubulointerstitial changes
2008 Rats IR: occlusion of infrarenal abdominal
aorta, ischemia 30 min, reperfusion 60
min vs. sham
EPO 1000 U/kg s.c. 5 min before
ischemia
↓MDA levels, ↓SOD activity, ↓catalase
↓histopathological changes
2007 Rats IR: bilateral renal pedicle occlusion 1 day
after last EPO injection, ischemia 45 min;
reperfusion 24, 72 hr and 1 week
EPO 100 U/kg or 100 U/kg CEPO s.c. q.
2 days for 2 weeks vs. saline
CEPO: (no erythropoiesis) ↓apoptosis, ↓a-SMA
expression, ↑tubular epithelial cell proliferation,
↓SCr. EPO: ↑Hb, ↓in apoptosis & a-SMA (not as
marked as CEPO). CEPO more therapeutic than EPO.
2007 Rats IR: bilateral renal pedicle occlusion 1 day
after last EPO injection, ischemia 60 min;
reperfusion 24, 72 hr
EPO 100 U/kg s.c. every 2 days for 2
weeks (6 injections) vs. saline
↑HIF-1alpha-positive cells, ↑VEGF mRNA expression,
↓tubular hypoxia, ↓apoptotic and a-SMA-positive
interstitial cells
2008 Rats IR: bilateral renal pedicle occlusion 1 day
after last EPO dose, ischemia 45 min;
reperfusion 24, 72 hr and 1 week
EPO or CEPO as above for 2 weeks ↑peritubular capillary endothelial cells. CEPO may
protect kidneys from IR injury by promoting
angiogenesis.
2007 Pigs IR: unilateral nephrectomy; occlusion
renal artery for 1 hr 1 week later,
reperfusion 5 days
EPO 5000 U/kg IV at ischemia, then
1000 U/kg s.c. vs. no treatment
↓renal dysfunction, ↓cell death (histology at 5 days)
2006 Rats IR: bilateral renal pedicle occlusion,
ischemia 45 min; reperfusion 48 hr
EPO 500 U/kg i.p. 20 min before
ischemia
↓SCr, ↓urea, ↓histological injury, ↓tubular apoptosis
2006 Rats IR: bilateral renal pedicle occlusion,
ischemia 45 min; reperfusion 1-7 days
vs. sham/vehicle
EPO 5000 U/kg or DPO 25 μg/kg i.p.
at time of ischemia or 6 hr after
reperfusion
EPO & DPO at T0 and T6 -↓tubular apoptosis,
↓plasma creatinine/urea, ↑tubular regeneration (cell
proliferation and mitosis)
2005 Rats IR: R nephrectomy, clamp L pedicle 45
min and reperfusion 45 min and 24 hr
EPO 1000 U/kg and genistein (tyrosine
kinase inhibitor) 10 mg/kg 2 hr before
ischemia
↓SCr, ↓urea, ↓TNF-a and IL-2 expression
(proinflammatory mediators of I-R injury), ↓LDH
(indicates lipid peroxidation), ↓histological injury;
genistein reversed benefits of EPO
2004 Rats IR: uni/bilateral renal artery occlusion, 30
min ischemia, 24 or 48 hr reperfusion vs.
sham/vehicle
EPO 5000 U/kg i.p. 30 min before
ischemia
↓apoptosis, ↑regeneration, ↓casts, ↓plasma
creatinine in vitro: ↓apoptosis, ↑mitosis/DNA
synthesis
2004 Mice IR: bilateral renal artery occlusion, 30
min ischemia, 24 hr reperfusion vs.
sham/vehicle
EPO 1000 U/kg/day s.c. 3 days before
I-R, or EPO 1000 U/kg s.c. on
reperfusion
↓plasma creatinine, ↓plasma AST, ↓histological
injury, ↓kidney MPO and MDA levels
2004 Rats IR: bilateral renal pedicle occlusion, 45
min ischemia, 6 hr reperfusion vs. sham/
saline
EPO 300 U/kg i.v. 30 min before
ischemia, 5 or 3 min before
reperfusion
↓tubular apoptosis, ↓tubular (NAG) and reperfusion
(AST) injury, ↓histological injury, ↓SCr, better urine
flow, ↑creatinine clearance
2004 Rats IR: bilateral renal artery occlusion, 40
min ischemia, 48 (1) or 96 (2) hrs
reperfusion vs. sham/vehicle
1. EPO 200 U/kg i.p. at start. 6 and 24
hr after reperfusion; or 200 U/kg i.v.
and 4, 10, 24, 48 hr after reperfusion
↓plasma creatinine, ↓polyuria, ↓FENa, ↑AQP/NHE/
TSC expression (prevented down-regulation of
AQPs and Na+ transporters)
2003 Rats IR: bilateral renal artery occlusion, 45
min ischemia, ≤72 hr reperfusion vs.
sham/saline
EPO 3000 U/kg 24 hr pre I-R injury ↓SCr, ↓tubular necrosis, ↓tubular apoptosis, ↓tubular
cell proliferation ↑bcl-2 protein, ↓caspase 3 activity,
↓JNK expression, dose-dependent
2001 Rats IR: R kidney occlusion, 30 or 45 min
ischemia, simultaneous L nephrectomy,
≤ 96 hr reperfusion vs. sham/vehicle
EPO 500 or 3000 U/kg i.v. at ischemia
then s.c. 24, 48 hr after
↑HCt, ↓ mortality (severe ischemia group), ®SCr/
weight
IR = ischemia-reperfusion, ↑ = increased, ↓ = decrease(d), ® = the same level, MDA = malondialdehyde, SOD = superoxide dismutase (an antioxidant), CEPO =
carbamylated EPO, a-SMA = alpha-smooth muscle actin (associated with renal injury), SCr = serum creatinine, HIF-1 alpha = hypoxia inducible factor-alpha, VEGF =
vascular endothelial growth factor, mRNA = messenger RNA, DPO = darbepoietin, R = right, L = left, TNF-a = tumor necrosis factor-alpha, IL-2 = interleukin-2, LDH =
lactate dehydrogenase, PTC = proximal tubule cell, AST = aspartate aminotransferase (indicates reperfusion injury), MPO = myeloperoxidase, NAG = N-
acetylglutamate, FENa = fractional excretion of Na+, AQP = aquaporin, NHE = Na+/H+ exchanger, TSC = thiazide-sensitive sodium chloride cotransporter, bcl-2 =
oncogene activated by chromosome translocation in human B-cell lymphomas, JNK = c-Jun N-terminal kinase, HSP70 = heat shock protein 70.
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may be responsible for the erythropoietic effects of EPO,
whereas isoforms with a lower affinity for EPO binding
may have nonerythropoietic effects, such as tissue pro-
tection [12].
The cytoplasmic domains of the EPOR contain a
number of phosphotyrosines that are phosphorylated by
the activation of a member of the Janus-type protein
tyrosine kinase family (JAK2), which is bound to the
common beta subunit of the EPOR [13]. In addition to
activating the mitogen-activated protein kinase (MAPK),
phosphatidylinositol 3-kinase (PI3K), and protein kinase
B (Akt) pathway (Figure 1), phosphotyrosines also serve
as docking sites for signal transducer and activators of
transcription (STATs), such as STAT5. Dephosphoryla-
tion of JAK can be induced by phosphatase with the
consequent internalization and degradation of the EPO/
EPOR complex, which marks the end of EPO activity.
This prevents overactivation, which may lead to exces-
sive erythrocytosis [14].
Post-receptor (intracellular) effects of EPO
There are a number of common pathways through
which EPO exerts its erythropoietic effects that also
appear to confer tissue protection. EPO “classically”
binds to two EPORs, which become joined as a homo-
dimer and change. This activates JAK2, which is
bound to the common beta subunit of the EPOR [13]
and leads to phosphorylation of tyrosine residues of
the EPOR, which activates a number of signaling path-
ways (Figure 1).
EPO classically signals through the “signal transducer
and activator of transcription 5” (STAT-5) pathway.
The STAT proteins are direct substrates of Janus
kinases (JAKs), which results in tyrosine phosphoryla-
tion of the STATs as well as phosphorylation of the
Figure 1 The main pathways of the effects of EPO. The intracellular domain of the EPOR contains phosphotyrosines, which are
phosphorylated by activation of a member of the Janus-type protein tyrosine kinase family (JAK2) bound to the EPOR. These phosphotyrosines
serve as docking sites for signal transducer and activator of transcription 5 (STAT5) and activate the mitogen-activated protein kinase (MAPK),
phosphatidylinositol 3-kinase (PI3K), and protein kinase B (Akt) pathway. Akt stimulates IKK to phosphorylate, which phosphorylates the inhibitory
IkB protein causing it to dissociate from NF-kB resulting, which causes its activation (Modified from Anaesth Intensive Care 2011, in press).
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phosphorylation of Akt (Figure 1).
The principal component of pathways that promote
anti-apoptotic effects is Akt (Figure 2), which inactivates
caspases, the major mediators of apoptosis, mitochon-
drial dysfunction, and subsequent release of cytochrome
C[ 1 5 ] .E P O ’s ability to maintain cellular integrity and
prevent inflammatory apoptosis is closely linked to
maintenance of mitochondrial membrane potential,
modulation of Apaf-1, inhibition of cytochrome C
release, and inhibition of caspases. Recent data also indi-
cate that serum and glucocorticoid-regulated kinase-1
(SGK1) may contribute to the mediation of EPO’sr e n o -
protective effects [16].
The phosphorylation of mitogen-activated protein
kinases (MAPKs) appears to contribute to the cell pro-
tection EPO confers (Figure 2). Protein kinase C (PKC)
also is involved in inhibition of apoptosis and cell survi-
val. It regulates the EPO-induced erythroid proliferation
and differentiation [17] and interferes with phosphoryla-
tion of the EPOR, making it a likely upstream modulator
of the EPOR.
EPO may be involved in modulation of cellular cal-
cium homeostasis by increasing calcium influx [18].
Figure 2 Apoptotic pathways influenced by EPO. Activated STAT5 promotes transcription of promitogenic and antiapoptotic genes
associated with apoptotic regulation and cytoprotection. Akt promotes cell survival and antiapoptotic effects by 1) inhibiting forkhead
transcription factor (FOXO3a), a trigger for apoptosis; 2) inactivating glycogen synthase kinase 3b (GSK3b), thus preventing cell injury; 3) reducing
the activity of proapoptotic proteins Bad and Bax; 4) increasing the activity of antiapoptotic protein Bcl-2; 5) preventing cytochrome C release.
NF-kB prevents apoptosis by 1) inducing expression of the inhibitors of apoptotic protein (inh. AP 1&2) and the x-chromosome-linked IAP (X-
InhAP), which inhibits caspase 3, 7, and 9; 2) promoting induction of growth arrest and DNA damage protein (Gadd45b), which is associated
with cell cycle and DNA repair and suppression of apoptosis; and 3) by activating Bcl-xL. EPO induces heat shock protein 70 (HSP70), which
inhibits AIF moving into the nucleus, thus avoiding DNA fragmentation and apoptosis. HSP70 also prevents Apaf-1/cytochrome C (Cyto-C)
binding, a complex involved in proapoptotic caspase activation. NB: the + sign indicates activation and the - sign indicates inhibition. (Modified
from Anaesth Intensive Care 2011, in press).
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tory and cytokine response, is implicated in EPO signal-
ing. The cytoprotection of EPO partly depends on Akt
and subsequent NF-kB activation (Figures 1 and 2).
NF-kB plays a role in the release of EPO during HIF-1
induction; Akt can increase NF-kB and HIF-1 activation
with resultant increase in EPO expression [19].
Finally, induction of heat shock protein 70 (HSP70) by
EPO is related to renal protection in ischemic kidneys
[20]. HSP70 prevents apoptosis by inhibiting movement
of apoptosis inducing factor (AIF) to the nucleus [21]
and by preventing Apaf-1/cytochrome C binding in the
cytosol [22] (Figure 2).
Red blood cell effects of EPO
The principal physiological function of EPO is red blood
cell production, which results from a tightly controlled
proliferation and differentiation pathway [23]. Early
hematopoietic progenitor cells differentiate into burst-
forming unit-erythroid cells (BFU-Es). Continuous
stimulation with EPO triggers the differentiation of
CFU-Es into erythroblasts, which lose their nuclei to
form reticulocytes. After a few days, reticulocytes lose
reticulin and become erythrocytes (red blood cells). Reti-
culocytes and erythrocytes stop expressing EPOR and
cease being responsive to EPO [24].
EPO-binding to EPORs on erythroid progenitor cells
leads to activation of the JAK2-STAT5 signaling path-
way and phosphorylation of PI3K and Akt1 [25] (Figure
1). Akt-mediated phosphorylation of Bad in the Bad-
Bcl-xL complex releases the antiapoptotic protein Bcl-
xL, which suppresses erythroid progenitor cell apoptosis
[26]. Akt also is involved in several pathways that pro-
mote cell survival and antiapoptotic effects through inhi-
bition of FOXO3a, inactivation of GSK3b, induction of
XIAP, inactivation of caspases, and prevention of cyto-
chrome C release (Figure 2). These effects not only
enhance the erythropoietic properties of EPO but appear
to be important in the protection of other cell types and
may contribute to the reported neuronal and renal pro-
tective effects [25].
The pleiotropic effects of EPO
T h et i s s u ep r o t e c t i v eo r“pleiotropic” effects (from the
Greek, πlείων - pleion, meaning “more,” and τrέπειν -
trepein meaning “turn or convert”)o fE P Ob e y o n d
erythropoiesis have been shown in the kidney in many
animal and some clinical studies.
Its tissue protective effects may be elicited through the
EPOR homodimer via JAK2-STAT5 activation and inhi-
bition of apoptosis or may be mediated by a second
EPOR isoform heterodimer composed of an EPOR
monomer and the cytokine receptor, common beta sub-
unit (CD-131). For example, carbamylated EPO (CEPO)
does not bind to the classical EPOR isoform and is
devoid of hematopoietic activity (Table 1); however, it
can provide tissue protection in the kidney, supporting
the existence of a heteroreceptor EPO isoform, which
mediates tissue protection [27]. It is clear that the rela-
tionship of EPO with its receptor is extremely complex.
Therefore, further investigation is required to fully
understand the EPOR heterodimer isoform, and the
mechanisms and pathways involved in its tissue protec-
tive activity.
Renal protection
Animal and in vitro studies
Many animal studies have shown that EPO administra-
tion protects kidney tissue from damage and improves
renal function in ischemia-reperfusion (IR) and con-
trast-induced injury models of AKI (Tables 1 and 2)
[25,28-52] in which EPO reduced kidney dysfunction by
decreasing apoptosis. In addition, EPO has been shown
to reduce the expression of proinflammatory mediators,
TNF-alpha and IL-2, in IR renal injury and reverse the
effect of endotoxin on the antioxidant, renal superoxide
dismutase (SOD). These anti-inflammatory properties of
EPO also suggest involvement of the NF-kB pathway in
its kidney protection.
CEPO: The administration of carbamylated EPO
(CEPO), which does not bind to the classical EPOR, also
provides renal tissue-protective effects. In an IR rat
model, CEPO markedly reduced apoptosis and increased
tubular epithelial cell proliferation. Moreover, CEPO
was more protective against IR injury to tubular epithe-
lial cells than EPO in this study. In an in vitro model
performed by the same team, CEPO promoted more
capillary formation than EPO and also appeared to pro-
tect the kidneys from IR injury by promotion of angio-
genesis [52]. This protective effect requires mitogenesis
and endothelial progenitor cell differentiation, prolifera-
tion, and migration.
EPO activates endothelial nitric oxide synthase, and
this effect on the endothelium may be critical for the
renal tissue protective effects of EPO. EPO is an extre-
mely potent stimulator of endothelial progenitor cells,
whose function is partly dependent on nitric oxide bioa-
vailability. Endothelial progenitor cells appear to be
involved in endothelial recovery after injury. EPO limits
AKI in part by stimulating vascular repair and by mobi-
lizing endothelial progenitor cells and increasing tubular
cell proliferation [27]. These findings suggest that EPO
may exert a protective effect via an interaction with the
microvasculature.
Angiogenesis and EPO’s renoprotective effects may be
influenced by vascular endothelial growth factor
(VEGF). Nakano and colleagues found that the vascular
EPO/EPOR system promoted postischemic angiogenesis
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directly by promoting neovascularization and indirectly
by mobilising endothelial progenitor cells and bone mar-
row-derived proangiogenic cells [53]. It appears that
angiogenesis is impaired and blood vessels are less
responsive to VEGF in the absence of EPOR.
EPO in AKI
AKI is common in critically ill patients [54,55] and is
independently associated with increased mortality, and
with prolonged length of stay. It escalates both the
human and financial costs of care. Therefore, it seems
desirable to investigate treatments with potential to
ameliorate or prevent AKI.
Some injury pathways for AKI in the critically ill
include exposure to endogenous and exogenous toxins,
metabolic factors, ischemia and reperfusion insults,
neurohormonal activation, inflammation, and oxidative
stress. Of these, ischemia-reperfusion may be the most
common. EPO can prevent or reduce injury and assist
renal repair and recovery through limitation of apopto-
sis, promotion of neovascularization, anti-inflammatory
action, and tissue regeneration.
Investigation of potential treatments for AKI has had
limited success to date; however, from the results of ani-
mal and some limited preliminary human studies, thera-
peutic use of EPO seems promising for those “at risk”
for AKI.
Clinical trials of EPO in AKI
One randomized, placebo-controlled, clinical trial of
preoperative EPO in 71 patients who underwent elective
coronary artery bypass graft (CABG) surgery reported
renoprotective effects [56] (Table 3). EPO was given at a
Table 2 Animal studies of EPO in nonischemic models of AKI
Year Type AKI model EPO dose Outcome
2010 Rats Brain death + Perfused kidney
model
10 μg/kg EPO or CEPO IV, 4 hr brain
death, then kidney reperfusion in
perfused kidney model
EPO and CEPO: ↓expression of proinflammatory genes,
↓infiltration of polymorphonuclear cells in kidney,
preserved vascular integrity. CEPO more effective than
EPO. Kidney function fully restored with EPO and CEPO.
2010 Mice Aristolochic acid nephropathy DPO 0.1 mcg/kg wkly from day of
Aristolochic acid administration or on day
28
↑survival of tubular cells lead to ↓acute tubular injury,
interstitial inflammation and interstitial fibrosis.
2008 Rats CIN: Ioversol 2.9 g/kg iodine +
inhibition of prostaglandin and
NO synthesis
EPO 10,000 U/kg or asialoEPO 80 ng/g i.v.
1 hr before Ioversol
↓renal dysfunction and histological injury, ↓apoptosis,
↓caspase3-activated apoptosis in renal porcine epithelial
cells in vitro with ↑JAK2/STAT5 phosphorylation and
HSP70 expression; ↑JAK2/STAT5 phosphorylation and
HSP70 expression in rat kidneys in vivo.
2008 Rats in vitro /CIN: cisplatin 5.5 mg/kg
i.v.
EPO 5,000 U/kg i.v. OR equivalent peptide
mass of inactive EPO OR DPO 25 μg/kg
before cisplatin OR saline
EPO ↑HCt, ↓SCr; DPO also ↑HCt, ↓SCr. Clearance studies:
GFR and renal blood flow confirmed DPO renal
protection. ↓tubular apoptosis and necrosis with DPO.
DPO 48 hr after cisplatin was renoprotective.
2008 Mice CIN: i.p. cisplatin injection (10
mg/kg/day) for 2 days vs.
placebo. Follow-up 6 days.
EPO 1,000 U/kg i.p. daily ≤ 3 days before
cisplatin vs. vehicle
↓urea, ↓casts, ↑marrow stem cell (MSC) numbers
2007 Mice Endotoxemia: 2.5 mg/kg
endotoxin i.p.
(lipopolysaccharide); follow-up
16 hrs later
EPO 4000 U/kg 30 min before endotoxin
vs. vehicle
↑GFR (inulin clearance), ®MAP, ®Renal bld flow, ↑CRP,
®serum NO, EPO reversed the endotoxin effect on renal
SOD activity (SOD ↓ in control group).
2006 Rats CIN: (iothalamate), following
indomethacin and Nω nitro-L-
arginine methyl ester
EPO 3000 U/kg and 600 U/kg i.v. 24 and
2 hr pre-CIN induction vs. saline
Creatinine clearance preserved
2005 Rats Chronic kidney disease DPO s.c. 0.4 μg/kg/wk into 5/6 remnant
kidney rats after renal mass reduction
↑microvascular density, ↑endothelial proliferation,
preserved renal function (↓SCr), ↓scarring, ↑VEGF
expression
2004 Rats Hemorrhagic shock and
endotoxic shock
EPO 300 U/kg i.v. before resuscitation ↓renal dysfunction in hemorrhagic but not endotoxic
shock
2001 Rats CIN: cisplatin toxicity - i.p.
cisplatin injection 6 mg/kg vs.
placebo
EPO 100 U/kg i.p. before cisplatin, then
daily for 9 days vs. placebo
↑renal blood flow/GFR at 9 days, ↑ tubular regeneration,
↑tubular cell proliferation, ↑functional recovery
1994 Rats CIN: cisplatin toxicity - i.p.
cisplatin injection 7 mg/kg vs.
placebo
EPO 100 U/kg i.p. after cisplatin, then
daily for 9 days vs. placebo
↑functional recovery, ↑tubular regeneration, ↑DNA
synthesis
CEPO = carbamylated EPO, DPO = darbepoietin, ↑ = increased, ↓ = decrease(d), ® = same level, H2O2 = hydrogen peroxide, JAK2/STAT5/Akt = signaling
pathways of EPO, GSK-3b = glycogen synthase kinase 3 beta, mTOR = mammalian target of rapamycin, ERK = extracellular signal-regulated kinase, CIN =
contrast-induced nephropathy, NO = nitric oxide, HSP70 = heat shock protein 70, RPTE = renal proximal tubular epithelial, SCr = serum creatinine, MAP = mean
arterial pressure, SOD = superoxide dismutase (an antioxidant), VEGF = vascular endothelial growth factor.
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associated with a reduction in the incidence of AKI
from 29% to 8% (p = 0.035) and improved postoperative
renal function as indicated by a smaller increase in SCr
(% increase at 24 hours of 1% vs. 15%, p = 0.04) and a
smaller decline in estimated GFR (% change at 24 hours
of +3% vs. -5%, p = 0.04) postoperatively (Table 3).
A more recent and larger (n = 162) study (EARLYARF
trial) assessed EPO’s effect in ICU patients deemed at
risk for AKI (defined by a specific cutoff value of two
proximal tubular enzymes in urine: g-glutamyl transpep-
tidase [GGT] and alkaline phosphatase [ALP]) (Table 3)
[57]. EPO was given at 500 U/kg IV when a high GGT
× ALP product was detected and repeated 24 hours
later. The primary outcome of this study was the aver-
age percent creatinine increase from baseline to its peak
over 7 days. Unlike the study in CABG patients, this
trial found no renoprotective effect of EPO. The reasons
for these contradictory findings may be related to the
differences in design and methods used.
EARLYARF trial
The EARLYARF trial is the largest trial of EPO as a
nephroprotective agent. However, it suffered from sev-
eral important methodological limitations. First, it used
poorly validated biomarkers as predictors of high risk
for AKI. This approach, along with an untested cutoff
value to trigger participant inclusion, resulted in the
Table 3 Comparison EPO in CABG surgery vs. EARLYARF trials
EPO in CABG EARLYARF
Sample size 71 (EPO: 36, placebo: 35) 162 (EPO: 84, placebo: 78)
Patient
population
Elective CABG Aim: ICU patients at high risk of AKI; Obtained: critically ill
patients
Study design Prospective randomised double-blind, placebo-controlled trial Prospective randomised double-blind placebo-controlled, trial
EPO type and
dose
1 dose preop: 300 U/kg EPO or normal saline IV 2 doses: EPO-beta 500 U/kg to max 50,000 U or normal saline IV
Inclusion
criteria
> 18, elective CABG ↑ in GGT and ALP urine concentration product > 46.3
Exclusion
criteria
Emergent CABG, pre-existing AKI, on RRT, uncontrolled HT,
nephrotoxic drugs within 3 days of op, previous use of EPO
< 16 yr, no IDC, hematuria, rhabdomyolysis, myoglobinuria,
polycythemia, cytotoxic chemo, RRT or needs in 48 hr, stay ≤24
hr, survival ≤72 hr, prior RIFLE “failure”
Measurements Baseline SCr preop and 24, 72, and 120 hr postop Baseline creatinine: various versions of preop/pre-ICU creatinine,
including lowest on ICU admit/last ICU creatinine/minimum at 12
mo. Blood for creatinine and Cyst C and start for 4/24 creatinine
clearance
Age (mean) 66.7 61.6
Study groups:
EPO vs.
placebo
Baseline and intraoperative: no significant differences, most
OPCABG (77%) (+3valves in EPO group)
EPO group older (p = 0.011) and ↑ likelihood for sepsis (p < 0.05).
More placebo patients had AKI (not significant)
Primary
outcome
Incidence of AKI after CABG A priori: Average % plasmaCr↑ from baseline over 4-7 days.
Secondary
outcomes
Changes in SCr and eGFR (first 5 days postop), ICU and hospital
LOS, in-hospital mortality
AKIN & RIFLE AKI definitions, plasma cystatin C, need for dialysis,
death within 7/30/90 days;
AKI: Definition ≥50%↑ in SCr from preop baseline AKIN (creatinine and UO) and RIFLE (creatinine) definitions
AKI:
Proportion
EPO 8%, placebo 29%; p = 0.035 AKIN creatinine: EPO 45.2%, placebo 47.4%; RIFLE creatinine: EPO
23.8%, placebo 19.2%; AKIN UO: EPO 70.2%, placebo 51.3% (p =
0.016)
Results %SCr↑ at 24 hr: EPO 1 ± 3, placebo 15 ± 7 (p = 0.04). %SCr↑ at
120 hr: EPO 7 ± 4, placebo 27 ± 8 (p = 0.01). %eGFR↓ at 24 hr:
EPO 3 ± 3, placebo -5 ± 4 (p = 0.04). %eGFR↓ at 120 hr: EPO -4
± 3, placebo -13 ± 5 (p = 0.01)
No significant difference in 1° outcome or 2° outcomes except
AKI (AKIN UO). Of randomised pts without AKI initially (n = 104)
EPO patients had higher %plasmaCr↑: EPO 8.5 ± 27(n = 61),
Placebo -4.6 ± 18 (n = 47; p = 0.004).
Onset of
injury
Initiation of CABG operation Heterogenous. Time of injury estimated for subdivision analysis.
Samples from 6-12 hr after putative insult more predictive for AKI
(AUC = 0.69), dialysis, and death.
AKI
mechanism
CVS compromise, CPB exposure Heterogenous
Safety No symptomatic thrombosis or other adverse events in EPO
patients
No evidence for ↑intravascular thrombosis. EPO not associated
with ↑ in adverse events.
CABG = coronary artery bypass graft, GGT = g-glutamyl transpeptidase, ALP = alkaline phosphatase, chemo = chemotherapy, pre/post/intraop = pre/post/
intraoperative(ly), RRT = renal replacement therapy, HT = hypertension, IDC = indwelling catheter, RIFLE and AKIN = AKI classification systems, (S)Cr = (serum)
creatinine, Cyst C = cystatin C, OPCABG = off pump CABG, ICH = intracranial hemorrhage, LOS = length of stay, UO = urine output criteria, CVS = cardiovascular
system, CPB = cardiopulmonary bypass, I-R = ischemia reperfusion.
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o n l yt h o s ea tt r u eh i g hr i s kf o rA K I .T h et r a n s i e n t
increase in urinary GGT and ALP seen in this trial,
along with the uncertainty about the timing of the insult
in a heterogeneous cohort, limited the ability to draw
conclusions about the efficacy of early EPO administra-
tion. Importantly, the biomarkers selected to trigger pro-
tection against AKI by means of EPO therapy were very
poor in predicting AKI with a receiver operating charac-
teristic area under the curve of only 0.54. The decision
to randomize was based solely on these biomarkers and
did not take into account additional clinical factors that
might assist in determining the risk of AKI.
A second problem in this study relates to the inclu-
sion of patients with likely volume-responsive prerenal
AKI, which would likely reduce the study’sp o w e r ,t o
determine the true efficacy of EPO. Fractional sodium
excretion was low in most randomized patients, suggest-
ing intact renal sodium reabsorption. The exclusion or
identification and separate treatment of patients with
prerenal AKI may reduce their confounding effect on
results.
Third, serum creatinine measurements used for the
baseline in the primary outcome were based on incon-
sistent criteria and timing. Some were taken before or
around the time of ICU admission and others after add-
ing additional confounders to the analysis. For the vast
majority of patients, no creatinine measurement was
available. Thus, the diagnosis of AKI was based on a ret-
rospective (post-hoc) analysis using different criteria
(lowest creatinine on ICU admission, last ICU value,
lowest value at follow-up). These varying criteria can
influence the accuracy of any assessment.
Fourth, at randomization, approximately one third of
patients had already met the criteria for AKI, suggesting
that the intervention was relatively late in the process of
injury for many. In addition, the trial size was small
with clear limitations in statistical power.
Fifth, in patients with early AKI (> 30%), measurement
of the reduction in AKI stage and improved recovery
should replace the use of development of AKI as an
endpoint. RIFLE and AKIN classification systems can be
used in this way.
Sixth, there were baseline differences between the
s t u d yg r o u p s .F o re x a m p l e ,t h eE P Og r o u pw e r eo l d e r
and more likely to have sepsis (p < 0.05).
As discussed by the investigators, these limitations
make it impossible to use this study to exclude a poten-
tial therapeutic renoprotective effect of EPO.
Potential risks of EPO
Pure red cell aplasia
Despite the numerous benefits of EPO, there are some
risks. Pure red cell aplasia is a rare adverse event, which
is characterized by anemia, low reticulocyte count,
absence of erythroblasts, resistance to EPO, and neutra-
lizing antibodies against EPO [58]. This is an extremely
rare complication.
Cancer patients
EPO administration in patients with cancer has been
associated with increased mortality and enhanced tumor
growth [59]. The underlying mechanisms remain uncer-
tain, but patients with certain malignancies may be in a
hypercoagulable state, making EPO administration
unadvisable.
Thrombosis
Recent studies and clinical trials have found an
increased rate of thrombosis with EPO, which has
mainly been observed in patient groups with higher
than conventional levels of hemoglobin (> 120 g/L).
Exclusion of patients with hemoglobin >120 g/L from
clinical trials of EPO minimizes the risk for thrombosis.
Nonetheless, systematic assessment for thrombosis
should be performed in any EPO trials of critically ill
patients because they have an increased risk for
thrombosis.
Hypertension
Hypertension occurs in approximately 30% of patients
who receive long-term EPO treatment and appears to
involve increased endothelin release, upregulation of tis-
sue renin and angiotensin production, changes in the
balance of vasoactive substances (prostaglandin/prosta-
cyclin/thromboxane), and an elevation of calcium by
EPO (at least in chronic kidney disease) that impairs the
vasodilating action of nitric oxide. It is advisable that
patients with uncontrolled hypertension do not partici-
pate in trials of EPO in AKI.
Carbamylated EPO, a cytoprotective, nonerythropoie-
tic derivative of EPO may not exhibit the same risks as
EPO and holds great interest as a future tissue-protec-
tive therapy. However, it requires further experimental
testing before it can be safely evaluated in clinical trials.
EPO-AKI
EPO-AKI and EPO-Biomarkers are the two compo-
nents of the renal substudy of the EPO-TBI trial
(NCT00987454). EPO-TBI is a trial of EPO as cerebral
protection after traumatic brain injury, and the renal
substudy assesses the effect of EPO on the develop-
ment of acute kidney injury (AKI) and the response to
treatment using multiple renal biomarkers with differ-
ent time profiles in patients with traumatic brain
injury. Having recently sustained a timed physical
injury, this homogenous cohort lends itself to such a
study. AKI will be classified using methods based on
the RIFLE criteria. Baseline renal function will be
taken from a consistent source for all patients. With a
cohort of 606 patients, this will be the largest study of
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the probability of detecting a treatment effect. Further-
more, it will be the first EPO trial to incorporate active
risk assessment for thrombotic episodes. Weekly inter-
vals separate the doses of EPO (up to 3) in this trial to
allow time for clearance and to avoid excessively high
levels of EPO. In addition, patients with a known
malignancy and/or uncontrolled hypertension will be
excluded, thus minimizing risk to patients. In a para-
doxical way, the EPO-TBI trial provides a unique
opportunity to clarify the potential benefit of EPO as a
kidney protective agent. This trial also may provide
valuable insight into the mechanisms of EPO in AKI
and pave the way for further dedicated large scale
trials of EPO in AKI.
Conclusions
Many experimental studies and a strong biological ratio-
nale support the notion that EPO may be an effective
nephroprotective drug. Only two studies have assessed
its efficacy in this regard: one study of patients who
received elective coronary artery bypass grafting, and the
other in a heterogeneous group of critically ill patients.
The first showed benefit; the second did not. Thus,
there is uncertainty as to whether the experimental ben-
efits can be translated into clinical benefits. A study of
EPO in TBI, however, is now underway and will rando-
mize 606 patients to placebo or EPO. This study will
offer a unique opportunity to study, in a larger and
more homogeneous cohort, whether EPO does confer
renal protection in patients at risk of AKI. Until such
data are available or other studies emerge to provide
more clinical data, EPO remains an attractive but
unproven nephroprotective agent.
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